Robert Terbrueggen
Research Subjects
Robert Terbrueggen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aviva R. Jacobs
DxTerity Diagnostics
1 shared publication- Chang Hee Kim
GoDx, Madison, USA
1 shared publication Francisco Flores
Department of Research and Development, DxTerity Diagnostics, Rancho Dominguez, California
1 shared publicationHannah Catterall
Department of Research and Development, DxTerity Diagnostics, Rancho Dominguez, California
1 shared publicationKevin R. Shah
Department of Research and Development, DxTerity Diagnostics, Rancho Dominguez, California
1 shared publicationKrishna S. Morampudi
Department of Research and Development, DxTerity Diagnostics, Rancho Dominguez, California
1 shared publication
Latest Publications
- Open Access
Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels
Recent studies using data accrued from global SARS-CoV-2 vaccination efforts have demonstrated that breakthrough infections are correlated with levels of neutralizing antibodies. The decrease in neutralizing antibody titers of vaccinated individuals over time, combined with the emergence of more infectious variants of concern has resulted in waning vaccine efficacy against infection and a rise in breakthrough infections. Here we use a combination of neutralizing antibody measurements determined by a high throughput surrogate viral neutralization test (sVNT) together with published data from vaccine clinical trials and comparative plaque reduction neutralization test (PRNT) between SARS-CoV-2 variants to develop a model for vaccine efficacy (VE) against symptomatic infection. Vaccine efficacy estimates using this model show good concordance with real world data from the US and Israel. Our work demonstrates that appropriately calibrated neutralizing antibody measurements determined by high throughput sVNT can be used to provide a semi-quantitative estimate of protection against infection. Given the highly variable antibody levels among the vaccinated population, this model may be of use in identification of individuals with an elevated risk of breakthrough infections.
Open AccessPredicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels
Recent studies using data accrued from global SARS-CoV-2 vaccination efforts have demonstrated that breakthrough infections are correlated with levels of neutralizing antibodies. The decrease in neutralizing antibody titers of vaccinated individuals over time, combined with the emergence of more infectious variants of concern has resulted in waning vaccine efficacy against infection and a rise in breakthrough infections. Here we use a combination of neutralizing antibody measurements determined by a high throughput surrogate viral neutralization test (sVNT) together with published data from vaccine clinical trials and comparative plaque reduction neutralization test (PRNT) between SARS-CoV-2 variants to develop a model for vaccine efficacy (VE) against symptomatic infection. Vaccine efficacy estimates using this model show good concordance with real world data from the US and Israel. Our work demonstrates that appropriately calibrated neutralizing antibody measurements determined by high throughput sVNT can be used to provide a semi-quantitative estimate of protection against infection. Given the highly variable antibody levels among the vaccinated population, this model may be of use in identification of individuals with an elevated risk of breakthrough infections.
- 1 March 2015
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 17 (2) , 118-127
A Novel Technology for Multiplex Gene Expression Analysis Directly from Whole Blood Samples Stabilized at Ambient Temperature Using an RNA-Stabilizing Buffer
- 1 March 2015
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 17 (2) , 118-127
A Novel Technology for Multiplex Gene Expression Analysis Directly from Whole Blood Samples Stabilized at Ambient Temperature Using an RNA-Stabilizing Buffer